CAH vs COR
Cardinal Health Inc (CAH) and Cencora, Inc. (COR) are both filed with the SEC under Wholesale-Drugs, Proprietaries & Druggists' Sundries. COR is 1.1× CAH's size by market cap ($61.3B against $54.7B); COR trades at the higher fiscal-year P/E (40.4× against 36.5×); CAH reports the higher net margin (0.7% against 0.5%); COR grew sales faster over three years (+10.4% against +7.1%); and over the past year CAH returned +58.5% against COR's +11.7%.
| CAH | COR | |
|---|---|---|
| Last close | $234.55 | $322.03 |
| Market cap | $54.7B | $61.3B |
| P/E (FY) | 36.5× | 40.4× |
| P/S | 0.2× | 0.2× |
| EV/EBITDA | 19.2× | 17.6× |
| Gross margin | 3.7% | 3.6% |
| Operating margin | 1.0% | 0.8% |
| Net margin | 0.7% | 0.5% |
| Return on equity | — | 144.3% |
| Sales growth (3y) | +7.1% | +10.4% |
| EPS growth (3y) | — | -0.3% |
| Dividend yield | 0.9% | 0.7% |
| 1-year return | +58.5% | +11.7% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year, and the two differ: CAH FY2025 (ended 2025-06-30); COR FY2025 (ended 2025-09-30). A return on equity past ±100% — COR at 144.3% — divides earnings by an average filed equity base smaller in magnitude than the earnings themselves; the two columns are not on one scale. — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| CAH | COR | |
|---|---|---|
| Institutional holders (13F) | 1,418 | 1,423 |
| Insider buyers − sellers (180d) | — | +2 |
| Congressional trades disclosed (180d) | 1 | 6 |
| Executive-branch officials on file — trades disclosed (180d) | 3 | 4 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5. — no open-market Form 4 purchases or sales in the window.
CAH vs COR: common questions
- Is CAH bigger than COR?
- COR carries the larger market cap — $61.3B against $54.7B, both struck on 2026-08-27.
- Which trades at a higher P/E, CAH or COR?
- COR, at a fiscal-year 40.4× against 36.5× for CAH. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have CAH and COR performed over the past year?
- CAH returned +58.5% and COR +11.7%, measured on the trailing calendar year to the last close.
- How many institutions hold CAH and COR?
- 1,418 13F filers report a position in CAH and 1,423 in COR, on the latest quarter in the panel.
- Are CAH and COR in the same industry?
- Both are filed with the SEC under Wholesale-Drugs, Proprietaries & Druggists' Sundries, which is the classification this pairing is built on.
CAH overview → · COR overview → · CAH institutional ownership → · COR institutional ownership → · Congress and CAH → · Congress and COR → · Executive branch and CAH → · Executive branch and COR →
More in Wholesale-Drugs, Proprietaries & Druggists' Sundries: CAH vs MCK · COR vs MCK
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/cah-vs-cor